Neurocrine Needs A Meaningful Clinical Win To Break Out, And Crinecerfont Could Do ItSeeking Alpha • 08/25/23
Neurocrine Biosciences price target raised at Oppenheimer after FDA approves movement disorder treatmentMarket Watch • 08/21/23
Neurocrine Biosciences Announces FDA Approval of INGREZZA® (valbenazine) Capsules for the Treatment of Chorea Associated With Huntington's DiseasePRNewsWire • 08/18/23
Neurocrine (NBIX) Reports Q2 Earnings: What Key Metrics Have to SayZacks Investment Research • 08/01/23
Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Surpass EstimatesZacks Investment Research • 08/01/23
Neurocrine Biosciences Reports Second Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales GuidancePRNewsWire • 08/01/23
Neurocrine Biosciences Announces Appointment of Christine A. Poon to Board of DirectorsPRNewsWire • 07/11/23
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2023 Financial ResultsPRNewsWire • 07/11/23
Diurnal Ltd., a Neurocrine Biosciences Company, Presents Phase 3 Extension Study Data for Modified-Release Hydrocortisone in Patients with Congenital Adrenal Hyperplasia at ENDO 2023PRNewsWire • 06/15/23
Neurocrine Biosciences to Present at the Goldman Sachs 44th Annual Global Healthcare ConferencePRNewsWire • 06/08/23
Neurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data on Tardive Dyskinesia Improvement Regardless of Baseline Antipsychotic Use at 2023 Psych Congress ElevatePRNewsWire • 06/02/23
Neurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington's Disease in The Lancet NeurologyPRNewsWire • 05/19/23
Neurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data on Long-Term Improvements and Psychiatric Stability in Patients With Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder at the Schizophrenia International Research Society 2023 Annual CongressPRNewsWire • 05/15/23
Neurocrine Biosciences Presents Data on Treatment of Patients with Congenital Adrenal Hyperplasia at ECE 2023PRNewsWire • 05/12/23
Neurocrine Biosciences (NBIX) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/03/23
Neurocrine Biosciences to Present at the Bank of America Securities 2023 Healthcare ConferencePRNewsWire • 05/02/23
Neurocrine Biosciences Supports the Mental Health Community During Tardive Dyskinesia Awareness WeekPRNewsWire • 05/01/23
Neurocrine Biosciences: Today's Best Near-Term Cap-Gain Biotech Developer ProspectSeeking Alpha • 04/22/23
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2023 Financial ResultsPRNewsWire • 04/12/23